Androgen Deprivation Therapy, Castration-resistant Prostate Cancer
Conditions
Keywords
exercise, hormone therapy
Brief summary
This single arm, multi-site pilot study aims to evaluate the feasibility of recruiting and adherence to a 12 week home-based exercise intervention to be conducted in men with metastatic castration resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Thirty patients will be enrolled, with the expectation that 20-25 will complete all follow-up measures.
Detailed description
The purpose of this trial is to evaluate the feasibility and adherence to a home-based 12 week exercise intervention in mCRPC patients receiving ADT. It will also examine if a home-based exercise intervention can improve muscle strength, body composition, physical function, cardiopulmonary function fatigue, and patient reported outcomes (fatigue, depression, quality of life (QoL)).
Interventions
The intervention consists of aerobic and strength training \ 3 times per week for 12 weeks with each session lasting 1 hour. The progressive aerobic exercise will involve walking that varies from from 15 to 30 minutes done 2-4 times per week at an intensity from 40% to 65% of heart rate reserve. Therabands elastic bands will be used to perform 12 to 15 repetitions per exercise. Once a participant can comfortably complete 15 repetitions for all prescribed sets, they will increase resistance by moving up to the next band. The training volume increased from 1 set per exercise on week 1 to 3 sets by week 12.
Sponsors
Study design
Intervention model description
Single-arm study with \ 30 men being recruited and 20-25 who complete all aspects of the study.
Eligibility
Inclusion criteria
* Metastatic disease that has progressed despite castrate levels of testosterone (surgically or medically castrated, with testosterone levels of \< 50 ng/dL) receiving ADT. This will be verified by assessing total testosterone levels within 4 weeks prior to enrollment. * No current chemotherapy. * Patients may be receiving additional hormonal therapy agents including but not limited to antiandrogens (e.g. bicalutamide, enzalutamide) and CYP17 inhibitors (e.g. abiraterone). * Ability to engage safely in moderate exercise as determined by their treating physician. * Not previously engaged in regular exercise training (\<3 or more d/wk for \> 30 min/d or \<90 mins per week total including strength training, aerobic training, or walking) in the past 6 months. * Access to a computer or a smart phone for syncing and uploading wearable activity data. * Be able to speak and read English.
Exclusion criteria
* Any condition that causes severe pain with exertion. * History of bone fractures. * Active cardiovascular disease including any of the following: * New York Heart Association (NYHA) Grade II or greater congestive heart failure . * History of myocardial infarction or unstable angina within 6 months prior to Day 1. * History of stroke or transient ischemic attack within 6 months prior to Day 1. * Acute or chronic respiratory disease that is severe enough to compromise the ability of the participant to safely engage in exercise training protocol. * Acute or chronic bone/joint/muscular abnormalities compromising their ability to exercise. * Neurological conditions that affect balance and, or muscle strength. * Dementia, altered mental status or any psychiatric condition prohibiting the understanding or rendering of informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Patients Who Complete the Pre/Post Exercise Intervention Testing. | 12 weeks after baseline testing | To estimate the feasibility of a 12 week, home-based exercise intervention in metastatic castrate resistant prostate cancer (mCPRC) patients undergoing androgen deprivation therapy by reporting the percentage of patients who complete the pre/post testing following the intervention. This was calculated as the number of subjects who completed the trial compared to the total number who completed baseline testing. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Physical Function: 6m Walk | 12 weeks after baseline testing | The time to complete (in sec) the 6m rapid walk test will be performed. |
| Physical Function: Timed Up and Go | 12 weeks after baseline testing | The time to complete (in sec) the 2.44m (8 ft) timed up and go test will be performed as an indicator of agility, balance, and physical function. A lower total time is indicative of greater performance. |
| Physical Function: Stair Climb | 12 weeks after baseline testing | The time to climb a flight of stairs (in sec) will be performed as an indicator of functional strength, muscle power, and balance. A lower total time (and higher calculated power output) is indicative of greater performance. |
| Physical Function: 400m Walk | 12 weeks after baseline testing | The time to walk 400m (in sec) will be performed as an indicator of walking endurance and gait speed will be determined. A lower total time and higher gait speed indicates greater cardiorespiratory capacity and will be correlated with cardiopulmonary function scores (outcome 14). |
| Patient Reported Outcomes: Fatigue | 12 weeks after baseline testing | Fatigue will be measure using the Functional Assessment of Chronic Illness Therapy Fatigue, a 1 page form that uses a rating scale that goes from 0 to 52. It assesses the patient's fatigue levels in the last 7 days. It also measures how usual activities, performing work, walking, relationship, and enjoyment of life are affected by fatigue. A higher score indicates higher quality of life (and lower fatigue). |
| Patient Reported Outcomes: Quality of Life | 12 weeks after baseline testing | Quality of life will be measured using the Functional Assessment of Cancer Therapy-Prostate (FACT-P). The FACT-P is composed of both multi-item scales and single-item measures. These include physical, social, emotional, and functional well-being, along with an assessment of prostate-specific health status. five functional scales, three symptom scales, a global health status / QoL scale, and six single items. All of the individual questions are scored from 0-4 with total scores ranging between 0 and 156 where a higher number represents higher QoL. |
| Patient Reported Outcomes: Depression | 12 weeks after baseline testing | Depression will be measured using the Hospital Anxiety and Depression Scale, a concise, self-administered 1 page form that categorizes anxiety and depression. The total score goes from 0-21, and scores are categorized from minimal to severe depression/anxiety. Higher total scores indicate greater levels of depression. |
| Patient Reported Outcomes: Anxiety | 12 weeks after baseline testing | Depression will be measured using the Hospital Anxiety and Depression Scale, a concise, self-administered 1 page form that categorizes anxiety and depression. The total score goes from 0-21, and scores are categorized from minimal to severe depression/anxiety. Higher total scores indicate greater levels of depression. |
| Muscle Size (Cross-sectional Area) | 12 weeks after baseline testing | Muscle size will be analyzed using ultrasound of the vastus lateralis of the dominant leg. All assessments will be completed before and after the intervention to determine the muscle size. Higher muscle mass and quality are associated with greater muscle strength, physical function, QoL, and mortality. |
| Adherence to the Intervention | 12 weeks after baseline testing | To report the level of adherence to the exercise intervention in patients completing pre/post testing. Successful adherence to the program is completion of 75% of all prescribed exercise and will be assessed using wearable technology to track walking and exercise logs to track resistance training adherence. Adherence was determined as the number of exercise sessions attempted/completed over the total number of session prescribed. |
| Chest Press Maximal Strength | 12 weeks after baseline testing | Upper and lower body muscle strength will be assessed using the chest and leg presses. Maximal strength is defined as the highest load (kilograms) that the participant can successfully lift one time. Greater maximal strength is associated with greater physical function and QoL. |
| Chest Press Muscle Endurance | 12 weeks after baseline testing | Upper and lower body muscle endurance will be assessed using the chest and leg presses. Muscle endurance is the total number of repetitions completed using 70% of maximal load determined during muscle strength testing (outcome 12). Greater muscle endurance are associated with greater physical function and QoL. |
| Leg Press Maximal Strength | 12 weeks after baseline testing | Upper and lower body muscle strength will be assessed using the chest and leg presses. Maximal strength is defined as the highest load (kilograms) that the participant can successfully lift one time. Greater maximal strength is associated with greater physical function and QoL. |
| Leg Press Muscle Endurance | 12 weeks after baseline testing | Upper and lower body muscle endurance will be assessed using the chest and leg presses. Muscle endurance is the total number of repetitions completed using 70% of maximal load determined during muscle strength testing (outcome 12). Greater muscle endurance are associated with greater physical function and QoL. |
| Cardiopulmonary Function | 12 weeks after baseline testing | To report changes in cardiopulmonary function following the intervention. Cardiopulmonary function (VO2 peak) will be assessed using a graded exercise test on a treadmill. Patients will begin the test walking slowly on the treadmill and every two minutes, the grade and speed of the treadmill will be increased in a progressive manner until fatigue occurs. Respiratory gases will be collected throughout the test and analyzed using a metabolic cart to determine oxygen utilization and carbon dioxide production. The maximal oxygen uptake that is recorded will be used as a marker of aerobic fitness. |
| Lean Mass | 12 weeks after baseline testing | To report changes in total lean mass following the intervention. Total body lean mass will be measured using dual-energy x-ray absorptiometry (DXA) before and after the intervention. |
| Fat Mass | 12 weeks after baseline testing | To report changes in total fat mass following the intervention. Total fat mass will be measured using dual-energy x-ray absorptiometry (DXA) before and after the intervention. |
| Percent Body Fat | 12 weeks after baseline testing | To report changes in relative fat mass following the intervention. Total body percent fat (percentage of fat mass relative to total mass) will be measured using dual-energy x-ray absorptiometry (DXA) before and after the intervention. |
| Muscle Quality | 12 weeks after baseline testing | Muscle architecture will be analyzed using ultrasound of the vastus lateralis of the dominant leg. All assessments will be completed before and after the intervention to determine the muscle quality. Higher muscle mass and quality are associated with greater muscle strength, physical function, QoL, and mortality. Muscle quality is reported in arbitrary units, where a lower value indicates a higher/better muscle quality. |
Countries
United States
Participant flow
Recruitment details
Subjects were recruited from 4/16/2017 through 12/5/2019 from referrals from medical oncologists from three institutions.
Pre-assignment details
62 subjects were referred to the study. Of this, 40 did not participate or qualify for the study. 22 subjects were consented and 16 completed all aspects of the trial.
Participants by arm
| Arm | Count |
|---|---|
| Home-based Exercise The sole intervention group will complete a combination of aerobic and strength training \
3 times per week for 12 weeks with each session lasting 1 hour.
Home-based exercise: The intervention consists of aerobic and strength training \
3 times per week for 12 weeks with each session lasting 1 hour. The progressive aerobic exercise will involve walking that varies from from 15 to 30 minutes done 2-4 times per week at an intensity from 40% to 65% of heart rate reserve. Therabands elastic bands will be used to perform 12 to 15 repetitions per exercise. Once a participant can comfortably complete 15 repetitions for all prescribed sets, they will increase resistance by moving up to the next band. The training volume increased from 1 set per exercise on week 1 to 3 sets by week 12. | 16 |
| Total | 16 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 1 |
| Overall Study | Physician Decision | 1 |
| Overall Study | Withdrawal by Subject | 4 |
Baseline characteristics
| Characteristic | Home-based Exercise |
|---|---|
| Age, Continuous | 72 years STANDARD_DEVIATION 7 |
| Body Mass Index | 28.90 kg/m^2 STANDARD_DEVIATION 6 |
| Duration of Androgen Deprivation Therapy (ADT) | 1132 days STANDARD_DEVIATION 1369 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 16 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Height | 172.4 cm STANDARD_DEVIATION 4.6 |
| Mass | 86.2 kg STANDARD_DEVIATION 19.6 |
| Previous Chemotherapy | 5 Participants |
| Previous Prostatectomy | 7 Participants |
| Previous Radiotherapy | 11 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 13 Participants |
| Region of Enrollment United States | 16 participants |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 16 Participants |
| Time since Chemotherapy | 13 months STANDARD_DEVIATION 5 |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 22 |
| other Total, other adverse events | 1 / 22 |
| serious Total, serious adverse events | 0 / 22 |
Outcome results
Percentage of Patients Who Complete the Pre/Post Exercise Intervention Testing.
To estimate the feasibility of a 12 week, home-based exercise intervention in metastatic castrate resistant prostate cancer (mCPRC) patients undergoing androgen deprivation therapy by reporting the percentage of patients who complete the pre/post testing following the intervention. This was calculated as the number of subjects who completed the trial compared to the total number who completed baseline testing.
Time frame: 12 weeks after baseline testing
Population: All participants in the trial.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Home-based Exercise | Percentage of Patients Who Complete the Pre/Post Exercise Intervention Testing. | 16 Participants |
Adherence to the Intervention
To report the level of adherence to the exercise intervention in patients completing pre/post testing. Successful adherence to the program is completion of 75% of all prescribed exercise and will be assessed using wearable technology to track walking and exercise logs to track resistance training adherence. Adherence was determined as the number of exercise sessions attempted/completed over the total number of session prescribed.
Time frame: 12 weeks after baseline testing
Population: This analysis was restricted to subjects who completed the intervention and returned their training logs.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Home-based Exercise | Adherence to the Intervention | Overall | 80.1 percentage of total sessions prescribed |
| Home-based Exercise | Adherence to the Intervention | Walking | 65.5 percentage of total sessions prescribed |
| Home-based Exercise | Adherence to the Intervention | Resistance Training | 72.8 percentage of total sessions prescribed |
Cardiopulmonary Function
To report changes in cardiopulmonary function following the intervention. Cardiopulmonary function (VO2 peak) will be assessed using a graded exercise test on a treadmill. Patients will begin the test walking slowly on the treadmill and every two minutes, the grade and speed of the treadmill will be increased in a progressive manner until fatigue occurs. Respiratory gases will be collected throughout the test and analyzed using a metabolic cart to determine oxygen utilization and carbon dioxide production. The maximal oxygen uptake that is recorded will be used as a marker of aerobic fitness.
Time frame: 12 weeks after baseline testing
Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Home-based Exercise | Cardiopulmonary Function | Baseline | 19.3 mL/kg/min | Standard Deviation 4 |
| Home-based Exercise | Cardiopulmonary Function | Post Intervention | 20.1 mL/kg/min | Standard Deviation 5.6 |
Chest Press Maximal Strength
Upper and lower body muscle strength will be assessed using the chest and leg presses. Maximal strength is defined as the highest load (kilograms) that the participant can successfully lift one time. Greater maximal strength is associated with greater physical function and QoL.
Time frame: 12 weeks after baseline testing
Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and were tested at the UNC site.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Home-based Exercise | Chest Press Maximal Strength | Baseline | 62.4 kg | Standard Deviation 21.4 |
| Home-based Exercise | Chest Press Maximal Strength | Post Intervention | 62.0 kg | Standard Deviation 13.3 |
Chest Press Muscle Endurance
Upper and lower body muscle endurance will be assessed using the chest and leg presses. Muscle endurance is the total number of repetitions completed using 70% of maximal load determined during muscle strength testing (outcome 12). Greater muscle endurance are associated with greater physical function and QoL.
Time frame: 12 weeks after baseline testing
Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and were tested at the UNC site.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Home-based Exercise | Chest Press Muscle Endurance | Baseline | 14.1 number of repetitions completed | Standard Deviation 5 |
| Home-based Exercise | Chest Press Muscle Endurance | Post Intervention | 15.4 number of repetitions completed | Standard Deviation 6.8 |
Fat Mass
To report changes in total fat mass following the intervention. Total fat mass will be measured using dual-energy x-ray absorptiometry (DXA) before and after the intervention.
Time frame: 12 weeks after baseline testing
Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and completed the body composition scans.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Home-based Exercise | Fat Mass | Baseline | 30 kg | Standard Deviation 12.9 |
| Home-based Exercise | Fat Mass | Post Intervention | 28.4 kg | Standard Deviation 15.2 |
Lean Mass
To report changes in total lean mass following the intervention. Total body lean mass will be measured using dual-energy x-ray absorptiometry (DXA) before and after the intervention.
Time frame: 12 weeks after baseline testing
Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and the body composition scans.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Home-based Exercise | Lean Mass | Baseline | 54.5 kg | Standard Deviation 8.6 |
| Home-based Exercise | Lean Mass | Post Intervention | 51.4 kg | Standard Deviation 16 |
Leg Press Maximal Strength
Upper and lower body muscle strength will be assessed using the chest and leg presses. Maximal strength is defined as the highest load (kilograms) that the participant can successfully lift one time. Greater maximal strength is associated with greater physical function and QoL.
Time frame: 12 weeks after baseline testing
Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and were tested at the UNC site.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Home-based Exercise | Leg Press Maximal Strength | Baseline | 142.1 kg | Standard Deviation 49.1 |
| Home-based Exercise | Leg Press Maximal Strength | Post Intervention | 141.5 kg | Standard Deviation 52 |
Leg Press Muscle Endurance
Upper and lower body muscle endurance will be assessed using the chest and leg presses. Muscle endurance is the total number of repetitions completed using 70% of maximal load determined during muscle strength testing (outcome 12). Greater muscle endurance are associated with greater physical function and QoL.
Time frame: 12 weeks after baseline testing
Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and were tested at the UNC site.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Home-based Exercise | Leg Press Muscle Endurance | Post Intervention | 14.1 number of repetitions completed | Standard Deviation 6.4 |
| Home-based Exercise | Leg Press Muscle Endurance | Baseline | 11.8 number of repetitions completed | Standard Deviation 6.7 |
Muscle Quality
Muscle architecture will be analyzed using ultrasound of the vastus lateralis of the dominant leg. All assessments will be completed before and after the intervention to determine the muscle quality. Higher muscle mass and quality are associated with greater muscle strength, physical function, QoL, and mortality. Muscle quality is reported in arbitrary units, where a lower value indicates a higher/better muscle quality.
Time frame: 12 weeks after baseline testing
Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and were tested at the UNC site.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Home-based Exercise | Muscle Quality | Baseline | 110.2 unitless | Standard Deviation 22 |
| Home-based Exercise | Muscle Quality | Post Intervention | 114.3 unitless | Standard Deviation 16.6 |
Muscle Size (Cross-sectional Area)
Muscle size will be analyzed using ultrasound of the vastus lateralis of the dominant leg. All assessments will be completed before and after the intervention to determine the muscle size. Higher muscle mass and quality are associated with greater muscle strength, physical function, QoL, and mortality.
Time frame: 12 weeks after baseline testing
Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and were tested at the University of North Carolina (UNC) site only. Equipment to perform this analysis at the Wake Forest site was not available.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Home-based Exercise | Muscle Size (Cross-sectional Area) | Baseline | 8.3 cm^2 | Standard Deviation 2.9 |
| Home-based Exercise | Muscle Size (Cross-sectional Area) | Post Intervention | 10.2 cm^2 | Standard Deviation 4 |
Patient Reported Outcomes: Anxiety
Depression will be measured using the Hospital Anxiety and Depression Scale, a concise, self-administered 1 page form that categorizes anxiety and depression. The total score goes from 0-21, and scores are categorized from minimal to severe depression/anxiety. Higher total scores indicate greater levels of depression.
Time frame: 12 weeks after baseline testing
Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and returned the questionnaires.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Home-based Exercise | Patient Reported Outcomes: Anxiety | Baseline | 4 score on a scale | Standard Deviation 3 |
| Home-based Exercise | Patient Reported Outcomes: Anxiety | Post Intervention | 3 score on a scale | Standard Deviation 2 |
Patient Reported Outcomes: Depression
Depression will be measured using the Hospital Anxiety and Depression Scale, a concise, self-administered 1 page form that categorizes anxiety and depression. The total score goes from 0-21, and scores are categorized from minimal to severe depression/anxiety. Higher total scores indicate greater levels of depression.
Time frame: 12 weeks after baseline testing
Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and returned the questionnaires.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Home-based Exercise | Patient Reported Outcomes: Depression | Baseline | 3 score on a scale | Standard Deviation 2 |
| Home-based Exercise | Patient Reported Outcomes: Depression | Post Intervention | 3 score on a scale | Standard Deviation 3 |
Patient Reported Outcomes: Fatigue
Fatigue will be measure using the Functional Assessment of Chronic Illness Therapy Fatigue, a 1 page form that uses a rating scale that goes from 0 to 52. It assesses the patient's fatigue levels in the last 7 days. It also measures how usual activities, performing work, walking, relationship, and enjoyment of life are affected by fatigue. A higher score indicates higher quality of life (and lower fatigue).
Time frame: 12 weeks after baseline testing
Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and returned the questionnaires.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Home-based Exercise | Patient Reported Outcomes: Fatigue | Baseline | 39 score on a scale | Standard Deviation 10 |
| Home-based Exercise | Patient Reported Outcomes: Fatigue | Post Intervention | 40 score on a scale | Standard Deviation 11 |
Patient Reported Outcomes: Quality of Life
Quality of life will be measured using the Functional Assessment of Cancer Therapy-Prostate (FACT-P). The FACT-P is composed of both multi-item scales and single-item measures. These include physical, social, emotional, and functional well-being, along with an assessment of prostate-specific health status. five functional scales, three symptom scales, a global health status / QoL scale, and six single items. All of the individual questions are scored from 0-4 with total scores ranging between 0 and 156 where a higher number represents higher QoL.
Time frame: 12 weeks after baseline testing
Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and returned the questionnaires.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Home-based Exercise | Patient Reported Outcomes: Quality of Life | Baseline | 119 score on a scale | Standard Deviation 20 |
| Home-based Exercise | Patient Reported Outcomes: Quality of Life | Post Intervention | 119 score on a scale | Standard Deviation 16 |
Percent Body Fat
To report changes in relative fat mass following the intervention. Total body percent fat (percentage of fat mass relative to total mass) will be measured using dual-energy x-ray absorptiometry (DXA) before and after the intervention.
Time frame: 12 weeks after baseline testing
Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial and the body composition scans.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Home-based Exercise | Percent Body Fat | Baseline | 34.0 percentage of total body mass | Standard Deviation 6.1 |
| Home-based Exercise | Percent Body Fat | Post Intervention | 34.3 percentage of total body mass | Standard Deviation 6.6 |
Physical Function: 400m Walk
The time to walk 400m (in sec) will be performed as an indicator of walking endurance and gait speed will be determined. A lower total time and higher gait speed indicates greater cardiorespiratory capacity and will be correlated with cardiopulmonary function scores (outcome 14).
Time frame: 12 weeks after baseline testing
Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Home-based Exercise | Physical Function: 400m Walk | Post Intervention | 313.5 seconds | Standard Deviation 87.3 |
| Home-based Exercise | Physical Function: 400m Walk | Baseline | 329.8 seconds | Standard Deviation 97.8 |
Physical Function: 6m Walk
The time to complete (in sec) the 6m rapid walk test will be performed.
Time frame: 12 weeks after baseline testing
Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Home-based Exercise | Physical Function: 6m Walk | Baseline | 4.4 seconds | Standard Deviation 1.5 |
| Home-based Exercise | Physical Function: 6m Walk | Post Intervention | 4.5 seconds | Standard Deviation 1.5 |
Physical Function: Stair Climb
The time to climb a flight of stairs (in sec) will be performed as an indicator of functional strength, muscle power, and balance. A lower total time (and higher calculated power output) is indicative of greater performance.
Time frame: 12 weeks after baseline testing
Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Home-based Exercise | Physical Function: Stair Climb | Baseline | 6.4 seconds | Standard Deviation 2.8 |
| Home-based Exercise | Physical Function: Stair Climb | Post Intervention | 6.2 seconds | Standard Deviation 3.2 |
Physical Function: Timed Up and Go
The time to complete (in sec) the 2.44m (8 ft) timed up and go test will be performed as an indicator of agility, balance, and physical function. A lower total time is indicative of greater performance.
Time frame: 12 weeks after baseline testing
Population: Data from pre vs. post intervention were analyzed using a paired t-test only in subjects who completed all aspects of the trial.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Home-based Exercise | Physical Function: Timed Up and Go | Baseline | 10.4 seconds | Standard Deviation 9.1 |
| Home-based Exercise | Physical Function: Timed Up and Go | Post Intervention | 10.8 seconds | Standard Deviation 11 |